MET Form 4: Director Jeh C. Johnson adds 48 shares through dividend plan
Rhea-AI Filing Summary
MetLife, Inc. (MET) director Jeh C. Johnson reported a small non-derivative acquisition of company stock. The Form 4 shows an imputed reinvestment of dividends under the MetLife Deferred Compensation Plan for Non-Management Directors, resulting in an acquisition of 48 shares on 09/09/2025 at an imputed price of $79.29 per share. Following the transaction, the reporting person beneficially owned 6,838 shares. The filing was signed by an attorney-in-fact on 09/11/2025. The disclosure reflects a routine dividend reinvestment rather than an open-market purchase or exercise of options.
Positive
- Increased insider ownership: Reporting person beneficially owns 6,838 shares after the reinvestment, modestly increasing alignment with shareholders
- Proper disclosure: Transaction reported on Form 4 and signed by attorney-in-fact, demonstrating compliance with Section 16 reporting requirements
Negative
- None.
Insights
Routine dividend reinvestment; immaterial to valuation but increases insider stake modestly.
The reported 48-share acquisition is the result of dividend reinvestment under the company plan, not an active market trade. At $79.29 implied price, the transaction increases the director's direct holdings to 6,838 shares, a small change relative to typical institutional positions. There are no derivative exercises, sales, or other actions that would signal a change in insider sentiment or corporate control.
Disclosure meets Section 16 reporting standards; transaction appears procedural and non-material.
The Form 4 documents an imputed dividend reinvestment under the deferred compensation plan for non-management directors. Signature by an attorney-in-fact is noted. The filing aligns with standard insider reporting obligations and does not indicate any governance or compliance issues based on the provided information.